Condition category
Circulatory System
Date applied
08/09/2005
Date assigned
27/10/2005
Last edited
11/10/2016
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

Contact information

Type

Scientific

Primary contact

Dr Matthew Walters

ORCID ID

Contact details

Department of Medicine & Therapeutics
Western Infirmary
44 Church Street
Glasgow
G11 6NT
United Kingdom
+44 (0)141 211 2821
gcl203@clinmed.gla.ac.uk

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

N/A

Study information

Scientific title

Reversibility of impaired cerebrovascular reactivity in patients with hypertension: comparison of losartan and atenolol

Acronym

Study hypothesis

To investigate the effect of both losartan and atenolol upon impaired cerebrovascular reactivity in hypertension.

Ethics approval

West Ethics Committee of NHS Greater Glasgow and Clyde, 18/12/2003, ref: 03/118 (1)

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Not specified

Trial type

Treatment

Patient information sheet

Not available in web format, please use contact details to request a participant information sheet

Condition

Hypertension

Intervention

Patients will undergo baseline assessment of cerebrovascular reactivity. Mean flow velocity (MFV) in the middle cerebral artery (MCA) will be measured using transcranial Doppler. Each subject will then receive an intravenous infusion of acetazolamide after which MFV will be measured. MFV in the internal carotid artery and peripheral arterial stiffness using Sphygmocor will also be assessed pre- and post-infusion. Patients then receive a supply of either losartan and atenolol tablets for 4 weeks after which they will undergo cardiovascular reactivity (CVR) assessment as before. A 1-week washout period of no medication will follow, then the protocol repeated with the alternated tablet.

Intervention type

Drug

Phase

Not Applicable

Drug names

Losartan, atenolol

Primary outcome measures

Changes in cerebrovascular reactivity.

Secondary outcome measures

Not provided at time of registration

Overall trial start date

01/08/2004

Overall trial end date

01/02/2006

Reason abandoned

Eligibility

Participant inclusion criteria

1. Male: 50-80 years
2. Electrocardiogram (ECG) evidence of left ventricular hypertrophy (LVH)
3. Blood pressure (BP) 150-200/90-115

Participant type

Patient

Age group

Adult

Gender

Male

Target number of participants

13

Participant exclusion criteria

1. >70% internal carotid artery (ICA) stenosis
2. Middle cerebral artery (MCA) stenosis
3. Contra-indication to losartan, atenolol or acetazolamide
4. Serum creatinine >130 µmol/l
5. Prior treatment with angiotensin converting enzyme (ACE)-1/angiotensin II receptor blocker (ARB)/beta blocker unless able to stop 4 weeks prior to recruitment

Recruitment start date

01/08/2004

Recruitment end date

01/02/2006

Locations

Countries of recruitment

United Kingdom

Trial participating centre

Western Infirmary
Glasgow
G11 6NT
United Kingdom

Sponsor information

Organisation

University of Glasgow (UK)

Sponsor details

University Avenue
Glasgow
G11 6NT
United Kingdom
+44 (0)141 211 2176
pcn1w@clinmed.gla.ac.uk

Sponsor type

University/education

Website

Funders

Funder type

University/education

Funder name

University of Glasgow

Alternative name(s)

Funding Body Type

private sector organisation

Funding Body Subtype

academic

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes

11/10/2016: No publications found, verifying study status with principal investigator.